(Q35180595)

English

Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 August 2017

Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin (English)

1 reference

Europe PubMed Central

7 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Kavindra Nath

1

1 reference

Europe PubMed Central

7 August 2017

David S Nelson

2

1 reference

Europe PubMed Central

7 August 2017

Daniel F Heitjan

3

1 reference

Europe PubMed Central

7 August 2017

Dennis B Leeper

4

1 reference

Europe PubMed Central

7 August 2017

Rong Zhou

5

1 reference

Europe PubMed Central

7 August 2017

Jerry D Glickson

6

1 reference

Europe PubMed Central

7 August 2017

publication date

12 December 2014

1 reference

Europe PubMed Central

7 August 2017

NMR in Biomedicine

1 reference

Europe PubMed Central

7 August 2017

28

1 reference

Europe PubMed Central

7 August 2017

3

1 reference

Europe PubMed Central

7 August 2017

281-290

1 reference

Europe PubMed Central

7 August 2017

Thermal sensitisation by lonidamine of human melanoma cells grown at low extracellular pH.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

(31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

The monocarboxylate transporter family--Structure and functional characterization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

Defining the pHi-hyperthermia sensitivity relationship for the RIF-1 tumor in vivo: a 31P MR spectroscopy study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

Therapeutic efficacy as predicted by quantitative assessment of murine RIF-1 tumour pH and phosphorous metabolite response during hyperthermia: an in vivo 31P NMR study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

Noninvasive real-time monitoring of intracellular cancer cell metabolism and response to lonidamine treatment using diffusion weighted proton magnetic resonance spectroscopy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

Phase I trial of lonidamine with whole body hyperthermia in advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable B-cell neoplasms: a report of two pilot clinical trials and laboratory investigations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

Combination therapy: lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

Determination of absolute phosphate metabolite concentrations in RIF-1 tumors in vivo by 31P-1H-2H NMR spectroscopy using water as an internal intensity reference

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

13 July 2018

Enhanced drug delivery in rabbit VX2 tumours using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

27 September 2018

The development of lonidamine for benign prostatic hyperplasia and other indications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

27 September 2018

Creatine kinase, a magnetic resonance-detectable marker gene for quantification of liver-directed gene transfer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

27 September 2018

Metaiodobenzylguanidine and hyperglycemia augment tumor response to isolated limb perfusion in a rodent model of human melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

27 September 2018

Regulation of intracellular pH in human melanoma: potential therapeutic implications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

27 September 2018

Enhancement of hyperglycemia-induced acidification of human melanoma xenografts with inhibitors of respiration and ion transport

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

27 September 2018

Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

27 September 2018

Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361034

27 September 2018

Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results from a multicenter prospective randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FNBM.3240

21 January 2018

Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25504852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potentiation of radiation effects on multicellular tumor spheroids (MTS) of HeLa cells by lonidamine

1 reference

https://pubmed.ncbi.nlm.nih.gov/25504852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and clinical pharmacologic evaluation of Lonidamine in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25504852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The combined use of radiation therapy and lonidamine in the treatment of brain metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/25504852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intracellular acidification of human melanoma xenografts by the respiratory inhibitor m-iodobenzylguanidine plus hyperglycemia: a 31P magnetic resonance spectroscopy study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25504852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanism of action of the antineoplastic drug lonidamine: 31P and 13C nuclear magnetic resonance studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/25504852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Whole-body hyperthermia and lonidamine as adjuvant therapy to treatment with cisplatin with or without local radiation in mouse bearing the Lewis lung carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25504852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

31P nuclear magnetic resonance spectroscopy studies of tumor energy metabolism and its relationship to intracapillary oxyhemoglobin saturation status and tumor hypoxia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25504852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship of Breast Magnetic Resonance Imaging to Outcome After Breast-Conservation Treatment With Radiation for Women With Early-Stage Invasive Breast Carcinoma or Ductal Carcinoma in Situ

1 reference

https://pubmed.ncbi.nlm.nih.gov/25504852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lonidamine: a hyperthermic sensitizer of HeLa cells in culture and of the Meth-A tumor in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/25504852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiosensitization of Meth-A fibrosarcoma in mice by Lonidamine

1 reference

https://pubmed.ncbi.nlm.nih.gov/25504852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Growth and metastasis of fresh human melanoma tissue in mice with severe combined immunodeficiency

1 reference

https://pubmed.ncbi.nlm.nih.gov/25504852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25504852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lonidamine alone and in combination with other chemotherapeutic agents in the treatment of cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25504852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics

1 reference

https://pubmed.ncbi.nlm.nih.gov/25504852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potentiation of radiation effects on two murine tumors by lonidamine

1 reference

https://pubmed.ncbi.nlm.nih.gov/25504852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG)

1 reference

https://pubmed.ncbi.nlm.nih.gov/25504852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/NBM.3240

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35180595&oldid=1991101126"